Niacin and cholesterol: Role in cardiovascular disease (Review)

Journal of Nutritional Biochemistry

Volumn 14, Issue 6, 2003, Pages 298-305

  Ganji, Shobha H ^a,b   Kamanna, Vaijinath S ^a,b   Kashyap, Moti L ^a,b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; CHOLESTEROL; CHOLESTEROL ESTER; DIACYLGLYCEROL ACYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VITAMIN;

ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; CATABOLISM; CELL LINE; CELL STRAIN HEPG2; CHOLESTEROL TRANSPORT; CORONARY ARTERY ATHEROSCLEROSIS; ETIOLOGY; FATTY ACID TRANSPORT; HUMAN; HUMAN CELL; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER CELL; PROTEIN DEGRADATION; REVIEW;

EID: 0037626887     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-2863(02)00284-X     Document Type: Article

References (50)

1. Henderson L.M. Niacin. Annu Rev Nutr. 3:1983;289-307.
2. McCormick D.B. Niacin in modern nutrition in health and disease. Shils M.E., Young V.R. 1988;370-375 Lea and Febiger, Philadelphia.
3. Wong N.D., Kashyap M.L. Cholesterol and lipids. Wong N.D. Preventive cardiology. 2000;165-194 McGraw-Hill Companies, Inc. New York.
4. Stamler M., Wentworth D., Neeaton J.D. Is the relationship between serum cholesterol and risk of premature death from coronary heart desease continuous and graded? Findings in 356, 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 256:1986;2823-2828.
5. Kwiterovich P.O. Jr. State-of-the-art update and review. Clinical trials of lipid-lowering agents. Am J Cardiol. 82:1998;3U-17U.
6. Zambon A., Hokanson J.E. Lipoprotein classes and coronary disease regression. Curr Opin Lipidol. 9:1998;329-336.
7. Scanu A.M. Lipoprotein(a) A Genetic Risk Factor for Premature Coronary Heart Disease. JAMA. 267:1992;3326-3329.
8. Kashyap M.L. Mechanistic studies of high density lipoproteins. Am J Cardiol. 82:1998;42U-48U.
9. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol Veteran Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group . New Eng J Med. 341:1999;410-418.
10. Robins S.J., Collins D., Wittes J.T., et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT A randomized controlled trial . JAMA. 285:2001;1585-1591.
11. Ross R. The pathogenesis of atherosclerosis-an update. N Eng J Med. 314:1986;488-500.
12. Ross R. Atherosclerosis-An Inflammatory Disease. New Eng J Med. 340:1999;115-126.
13. Libby P. Heart Disease. Brauneald E., Zipes D.P., Libby P. A text book of cardiovascular medicine. 6th ed: 2001;W. B. Saunders.
14. Goldstein J.L., Ho Y.K., Basu S.K., et al. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoproteins, producing massive cholesterol deposition. Proc Natl Acad Sci USA. 76:1979;333-337.
15. Steinberg D. low density lipoprotein oxidation and its pathobiological significance. J Biol Chem. 272:1997;20963-20966.
16. Ross R. The pathogenesis of atherosclerosis, a perspective for the 1990s. Nature. 362:1993;801-809.
17. Kamanna V.S., Bassa B.V., Kirschenbaum M.A. Atherogenic lipoproteins and human disease extending concepts beyond the heart to the kidney . Currn Opin Nephrol and Hypertension. 6:1997;205-211.
18. Liao J.K. Endothelium and acute coronary syndromes. Clin Chem. 44:1998;1799-1808.
19. Banka C.L. High density lipoprotein and lipoprotein oxidation. Current Opin Lipidol. 7:1996;139-142.
20. Navab M., Imes S.S., Hama S.Y., et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest. 88:1991;2039-2046.
21. Cockerill G.W., Rye K.A., Gamble J.R., et al. HDL inhibits cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol. 15:1995;1987-1994.
22. Navab M., Hama S.Y., Hough G.P., et al. High density associated enzymes. Their role in vascular biology. Current Opin Lipidol. 9:1998;449-456.
23. Altschul R., Hoffer A., Stephen J.D. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys. 54:1955;558-559.
24. Weiner M., Eys V. In Nicotinic acid, nutrient-cofactor-drug. 1983;227-299 Dekker, New York.
25. Tavintharan S., Kashyap M.L. The benefits of niacin in atherosclerosis. Current Atherosclerosis Reports. 3:2001;74-82.
26. Carlson L.A., Oro L., Ostman J. Effect of single dose of nicotinic acid on plasma lipids in patients with hyperlipoproteinemia. Acta Med Scand. 183:1968;457-465.
27. Aktories K., Schultz G., Jakobs K.H. Regulation of adenylate cyclase activity in hamster adipocytes. Naunyn-Schmiedeberg's Arch Pharmacol. 312:1980;167-173.
28. Lacasa D., Agli B., Giudicelli Y. Increased sensitivity of fat cell adenylate cyclase to stimulatory agonists during fasting is not related to impaired inhibitory coupling system. FEBS Lett. 202:1986;260-266.
29. Lorenzen A., Stannek C., Lang H., et al. Characterization of a G protein-coupled receptor for nicotinic acid. Mol Pharmacol. 59:2001;349-357.
30. Kamanna V.S., Kashyap M.L. Mechanism of action of niacin on lipoprotein metabolism. Current Atherosclerosis Reports. 2:2000;36-46.
31. Ginsberg H.N. Synthesis and secretion of apolipoprotein B from cultured liver cells. Current Opin Lipidol. 6:1995;275-280.
32. Davis R.A. Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver. Biochim Biophys Acta. 1440:1999;1-31.
33. Dixon J.L., Furukawa S., Ginsberg H.N. Oleate stimulates secretion of apolipoprotein B-containing lipoproteins from Hep G2 cells by inhibiting early intracellular degradation of apolipoprotein B. J Biol Chem. 266:1991;5080-5086.
34. Wu X., Sakata N., Lui E., et al. Evidence for a lack of regulation of the assembly and secretion of apolipoprotein B-containing lipoprotein from Hep G2 cells by cholesteryl ester. J Biol Chem. 269:1994;12375-12382.
35. Cianflone K.M., Yasruel Z., Rodriguez M.A., et al. Regulation of apo B secretion from Hep G2 cells. Evidence for a critical role for cholesteryl ester synthesis in the response to a fatty acid challenge. J Lipid Res. 31:1990;2045-2055.
36. Grundy S.M., Mok H.Y.I., Zech L., Berman M. Influence of nicotinic acid aon metabolism of cholesterol and triglycerides in man. J Lipid Res. 22:1981;24-36.
37. Jin F.Y., Kamanna V.S., Kashyap M.L. Niacin accelerates intracellular apo B degradaqtion by inhibiting triacylglycerol synthesis in human hepatoblastoma (Hep G2) cells. Arterioscler Thromb Vasc Biol. 19:1999;1051-1059.
38. Ganji S.H., Tavintharan S., Zhu D., et al. Niacin non-competitively inhibits hepatocyte diacylglycerol acyltransferase, a key enzyme for triglyceride synthesis. Arterioscler Thromb Vasc Biol. 22:2002;878. (Abstract).
39. Barbaras R., Puchois P., Fruchart J.-C., Ailhaud G. Cholesterol efflux from cultured adipose cells is mediated by LP A-I particles but not by LP A-I A-II particles . Biochem Biophys Res Commun. 142:1987;63-69.
40. Rinninger F., Kaiser F., Windler E., et al. Selective uptake of cholesteryl esters from high- density lipoprotein derived LP A-I and LP A-I A-II particles by hepatic cells in culture . Biochim Biophys Acta. 1393:1998;277-291.
41. Puchois P., Kandoussi A., Fievet P., et al. Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis. 68:1987;35-40.
42. Amouyel P., Isorez D., Bard J.M., et al. Parental history of early myocardial infraction is associated with decreased levels of lipoparticle A-I in adolescents. Arterioscler Thromb. 13:1993;1640-1644.
43. Blum C.B., Levy J.R., Eisenberg S., et al. High density lipoprotein metabolism in man. J Clin Invest. 60:1977;795-807.
44. Shepherd J., Packard C.J., Patsch J.R., et al. Effect of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest. 63:1979;858-867.
45. Jin F.Y., Kamanna V.S., Kashyap M.L. Niacin decreases removal of high density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implications for reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 17:1997;2020-2028.
46. Acton S., Riggoti A., Landschutz K.T., et al. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 271:1996;518-520.
47. Hammad S.M., Steingrimur S., Twal W.O., et al. Cubilin, the endocytic receptor for intrinsic factor-vitamin B12 complex, mediates high-density lipoprotein holoparticle endocytosis. Proc Natl Acad Sci USA. 96:1999;10158-10163.
48. Kozyraki R., Fyfe J., Kristiansen M., et al. The intrinsic factor- vitamin B12, cubilin, is a high affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein. Nature Med. 5:1999;656-661.
49. Sakai T., Kamanna V.S., Kashyap M.L. Niacin but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol. 21:2001;1783-1789.
50. Zambon A., Hokanson J., Brown B.G., Brunzell J.D. Evidence for a new pathophysiological mechanism for coronary artery disease regression, hepatic lipase-mediated changes in LDL density. Circulation. 99:1999;1959-1964.